IMBDX

News

Early detection of cancer.

Media Library

게시물 목록
NO SUBJECT WRITE
6

IMBdx Acquires Taiwan SNQ National Quality Mark with AlphaLiquid100 Service

— Clinical credibility formally recognized through collaborative research with leading Taiwanese KOLs and publication in ESMO Open   IMBdx’s AlphaLiquid100, a body fluid–based liquid biopsy service, has received the 2025 SNQ (Symbol of National Quality) National Quality Mark in Taiwan, recognizing its clinical reliability and service quality. The platform enables high-performance cfDNA analysis across multiple body fluids, including blood, pleural effusion, ascites, cerebrospinal fluid, and bronchoalveolar lavage fluid, demonstrating strong applicability in real-world clinical practice. Through collaborative research with leading Taiwanese medical institutions and KOLs, IMBdx has built robust clinical evidence supporting the analytical performance and clinical utility of body fluid–based liquid biopsy. These efforts culminated in the publication of a pleural effusion–based cfDNA study in ESMO Open, which showed improved detection of actionable mutations compared to conventional molecular testing, including effective identification of acquired EGFR T790M mutations in advanced NSCLC. The SNQ certification confirms that IMBdx’s body fluid–based liquid biopsy delivers clinically validated performance as a reliable precision diagnostics service, extending beyond research into everyday patient care.   “IMBdx aims to establish liquid biopsy not merely as a diagnostic test, but as a reliable precision diagnostics infrastructure that can be trusted in everyday clinical practice.” “The SNQ certification and the publication in ESMO Open are particularly meaningful in that they reflect a continuous and integrated accumulation of research outcomes and service quality, both focused on creating tangible value for patient care.” “Moving forward, IMBdx will continue to expand clinical evidence based on high-quality liquid biopsy services and grow into a patient-centered global precision diagnostics company that supports cancer treatment decision-making and the entire patient journey.”

IMBdx Acquires Taiwan SNQ National Quality Mark with AlphaLiquid100 Service new

  • 2026-01-06
 2026-01-06
5

Korea's IMBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection for Liquid Biopsy Tech

  Korea's IMBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection for Liquid Biopsy Tech   IMBDx, a Korean cancer diagnostics company, is advancing its AlphaLiquid liquid biopsy technology for various applications, including lung cancer therapy guidance and multi-cancer early detection (MCED). The company's AlphaLiquid platform, which includes assays for tumor profiling, recurrence monitoring, and minimal residual disease detection, aims to improve cancer care. Their flagship AlphaLiquid 100 detects cancer-related mutations in plasma and pleural effusion samples, showing clinical utility in non-small cell lung cancer (NSCLC). IMBDx is also expanding its platform for use with other sample types, such as cerebrospinal fluid (CSF),  and stepping into the MCED space with CancerFind, which screens for eight cancer types.  The company is working to expand CancerFind to detect 30 cancers by 2029  through a project funded by Korea's ARPA-H, aiming for Korean FDA approval and global commercialization.  They are also collaborating with AstraZeneca on liquid biopsy diagnostics for targeted therapies in prostate cancer and other cancers.  IMBDx's efforts focus on integrating liquid biopsies into clinical guidelines to improve cancer care and outcomes.     [Publications] Enhanced Detection of Actionable Mutations in NSCLC Through Pleural Effusion Cell-Free DNA Sequencing: A Prospective Study Clinical utility and predictive value of cerebrospinal fluid cell-free DNA profiling in non-small cell lung cancer patients with leptomeningeal metastasis Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer   Full Article  

Korea's IMBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection for Liquid Biopsy Tech

  • 2025-03-04
 2025-03-04
4

IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership

South Korean liquid biopsy firm IMBdx said Thursday that it is expanding an ongoing collaboration with AstraZeneca under a project called PROSPER 2.0, which aims to improve access to targeted therapies for individuals with metastatic prostate cancer in markets outside the US. Financial terms of the partnership were not disclosed. IMBdx offers a blood-based next-generation sequencing test called AlphaLiquid HRR, which analyzes circulating tumor DNA in plasma to detect alterations in 15 genes associated with homologous recombination repair. The assay is currently available in various countries including Ukraine, Australia, Taiwan, Malaysia, Vietnam, Colombia, Mexico, Lebanon, United Arab Emirates, Saudi Arabia, and Kuwait, the company said. As part of the PROSPER 2.0 project, IMBdx and AstraZeneca are exploring ways to increase clinician and patient awareness of the availability and utility of ctDNA testing to guide the use of targeted therapies in advanced prostate cancer, and of the capabilities of the AlphaLiquid HRR ctDNA test in particular. IMBdx said it has been developing the test for more than two years, including in a collaborative study with Seoul National University Hospital that provided HRR results for 92 percent of patients using blood samples and demonstrated high concordance with tissue biopsy results.   GenomeWeb, 2023

IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership file

  • 2023-06-08
 2023-06-08
3

IMBDx Attends 'KoreaBIO X BioCentury X Sidley Austin 2021 Global IR' for Domestic Bio Startups

On January 21st, 2021 IMB Dx attended the 'KoreaBIO X BioCentury X Sidley Austin 2021 Global IR,' held for the purpose of supporting Korean biotech startups with global network building and overseas expansion.    As an additional event to the JP Morgan Healthcare Conference, this online event was sponsored by the Korea Biotechnology Industry Organization (Korea BIO), BioCentury, and Sidley Austin LLP. At the event, IMB Dx CEO Peter Moon pitched the company's outstanding potential and technologies for global expansion and investment attraction.   Watch CEO Moon pitching at the Global IR event below, followed by a short video of him introducing AlphaLiquid®100, filmed with the support of Invest Korea.    

IMBDx Attends 'KoreaBIO X BioCentury X Sidley Austin 2021 Global IR' for Domestic Bio Startups file

  • 2021-02-10
 2021-02-10
2

IMBDx to Attend Bio Health Worldwide Online 2020

  IMB Dx is attending the ‘Bio Health Worldwide Online 2020’ exhibit sponsored by KOTRA and the South Korean Ministry of Trade, Industry and Energy which will be held for 12 days beginning October 19th, 2020.  Over 500 companies in the fields of biotechnology, pharmaceutical, medical device, healthcare, dietary supplements, and protective supplies, as well as over 1,000 potential buyers fr|om all over the world, are expected to attend. The exhibit will be held entirely virtually due to COVID-19.   At its virtual exhibition booth, IMB Dx will be presenting its liquid biopsy platform, the AlphaLiquid® product series, which detects and monitors minuscule amount of tumor DNA in the blood with high sensitivity.  IMB Dx has already confirmed several meetings with various companies, including those fr|om China, Vietnam, and Germany, that have expressed interest in IMB Dx’s services.   IMB Dx official said that the company plans on “continuously participating in global partnership opportunities through programs like Bio Health Worldwide Online that support our global expansion.”  She added, “Liquid biopsy has recently risen as one of the most anticipated areas in the healthcare field, and we are now prepared better than ever to enter the global precision oncology market with our proprietary technology and competitive pricing.”    

IMBDx to Attend Bio Health Worldwide Online 2020 file

  • 2020-10-19
 2020-10-19